Before you sell to, join or invest in iBio, Inc.
MentionFox check on iBio, Inc.: no red flags found in 3 sources; 1 item to note (checked 4 November 2026). mentionfox.com/c/funding/ibio-inc-form-d-25000001
Check iBio, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
What do you want to do about iBio, Inc.?
Based on the records MentionFox holds for this company. No flag is not a clearance.
iBio, Inc. filed a Form D with the Securities and Exchange Commission on 2025-05-07.
iBio, Inc. filed a Form D notice of an exempt securities offering with the SEC on May 7, 2025. iBio, Inc. trades on Nasdaq as IBIO. The filing reports $11.08M sold. Its industry group is Biotechnology. It names Martin Brenner (Executive Officer, Director), Felipe Duran (Executive Officer), Evert Shimmelpennink (Director) (SEC Form D, May 7, 2025).
In its own words: “iBio develops novel therapies for obesity and cardiometabolic disorders using its patented AI drug discovery platform.” (ibioinc.com, checked November 3, 2026)
Is this your company?
Sell to companies like iBio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-05-07 · the record
Pitching, partnering or investing alongside them? See who really runs and owns iBio, Inc.
Free to see. No signup.
More on the people and the money behind iBio, Inc., from the filings we hold.
Biotechnology raises by companies based in California, filed in May 2025, largest first.
Get an email when iBio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when iBio, Inc. raises, hires or launches. No email unless you switch it on.
Watch iBio, Inc. →Get the full cited report on iBio, Inc.
What the filing shows about iBio, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on iBio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives iBio, Inc.'s address as 11750 Sorrento Valley Road, Suite 200, San Diego, CA 92121.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for iBio, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
iBio, Inc. is a registered filer with the SEC (CIK 1420720) and has filed since 2023-08-15. 4 filings are on record, the latest on 2026-01-22.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
iBio, Inc.'s Form D of 2025-05-07 names Martin Brenner, Felipe Duran, Evert Shimmelpennink and 6 more as its officers, directors or promoters.
Its new offerings report $52.14M sold across 3 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
While no offering proceeds are set aside for payments to named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers.
Checked away from the filing. What is below does not come from the record on sec.gov.
iBio develops novel therapies for obesity and cardiometabolic disorders using its patented AI drug discovery platform.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Martin Brenner is named as Executive Officer and Director on the Form D that iBio, Inc. filed with the SEC on 7 May 2025, one of 9 people that filing names.
Felipe Duran is named as Executive Officer on the Form D that iBio, Inc. filed with the SEC on 7 May 2025, one of 9 people that filing names.
Evert Shimmelpennink is named as Director on the Form D that iBio, Inc. filed with the SEC on 7 May 2025, one of 9 people that filing names.
Alexandra Kroptova is named as Director on the Form D that iBio, Inc. filed with the SEC on 7 May 2025, one of 9 people that filing names.
William Clark is named as Director on the Form D that iBio, Inc. filed with the SEC on 7 May 2025, one of 9 people that filing names.
Gary Sender is named as Director on the Form D that iBio, Inc. filed with the SEC on 7 May 2025, one of 9 people that filing names.
David Arkowitz is named as Director on the Form D that iBio, Inc. filed with the SEC on 7 May 2025, one of 9 people that filing names.
Antonio Parada is named as Director on the Form D that iBio, Inc. filed with the SEC on 7 May 2025, one of 9 people that filing names.
Marc Banjak is named as Executive Officer on the Form D that iBio, Inc. filed with the SEC on 7 May 2025, one of 9 people that filing names.
9 people named on the filing — 3 holding an executive role and 6 as directors only.
Named as of the 2025-05-07 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about iBio, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on iBio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on iBio, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist iBio, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind iBio, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-11-04 (ibioinc.com).
Each opens in a new tab, filled in for iBio, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in San Diego
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/ibio-inc-form-d-25000001